Signs memorandum of understanding with the Food and Drug Administration of the Islamic Republic of Iran
Novo Nordisk is to build a €70m manufacturing plant for FlexPen prefilled insulin devices in Iran in a five-year project.
The Danish insulin specialist already employs around 130 people in the country and said the new facility will create 160 jobs. Once completed, it will function in compliance with Good Manufacturing Practices (GMP).
The new plant 'signals our long-term commitment to Iran, a country where close to five million people have diabetes according to the International Diabetes Federation', said Ole Moelskov Bech, Corporate Vice President of Novo Nordisk Business Area Near East.
'This investment will ensure availability of our modern insulins and will bring us a step closer to the people who rely on our products.'